Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Access to Genetic Testing in Underserved Patients With Cancer

NCT06422455 · View on ClinicalTrials.gov ↗

Study Summary

This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human genetics healthcare provider. Patients with cancer are increasingly recommended for genetic testing as standard of care. Multiple factors contribute to low usage of genetic testing but for many patients the lack of access to genetic counseling and testing is an important and flexible factor. Lack of access is especially relevant to racial/ethnic minority patients and those living in non-metropolitan rural settings who are frequently cared for at safety-net hospitals with limited genetics services. Alternative delivery models are necessary to improve rates of access to genetic testing in patients with cancer. Health information technology is under used by genetics providers. A patient-facing relational agent (PERLA) will provide pre-test genetics education in both English and Spanish across two clinical settings to facilitate more timely access to genetic testing. Using the PERLA intervention may help researchers learn different ways to provide education about genetic testing to patients with cancer compared to usual care.

Interventions

  • OTHER Best Practice
  • OTHER Educational Intervention
  • OTHER Electronic Health Record Review
  • OTHER Interview
  • OTHER Genetic Counseling

Study Locations (2)

California

  • USC / Norris Comprehensive Cancer Center — Los Angeles

New York

  • University of Rochester — Rochester

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2023-10-24
Est. Completion 2028-10-24
Phase NA

Sponsor

University of Southern California

412 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06422455

The ClinicalTrials.gov registry entry for NCT06422455 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 412 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 8 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 5 interventions — of which Best Practice is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06422455 reports 2 study locations spanning 2 distinct geographic areas — top geographies include California, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06422455 about?

NCT06422455 is a clinical study titled "Access to Genetic Testing in Underserved Patients With Cancer". This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human genetics healthcare provider. Patients with cancer are increasingly recommended for genetic testing as standard of care. Mu...

What is the current status of trial NCT06422455?

This trial is currently recruiting. It is a NA study. The enrollment target is 800 participants. The study started on 2023-10-24. Estimated completion is 2028-10-24.

What conditions does trial NCT06422455 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Breast Carcinoma, Metastatic Prostate Carcinoma, Ovarian Carcinoma, Triple-Negative Breast Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06422455?

The interventions under investigation include: Best Practice (OTHER), Educational Intervention (OTHER), Electronic Health Record Review (OTHER), Interview (OTHER), Genetic Counseling (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06422455?

This trial is sponsored by University of Southern California, which has 412 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06422455 being conducted?

This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial